Specify a stock or a cryptocurrency in the search bar to get a summary
Cogent Biosciences Inc
COGTCogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts. Address: 275 Wyman Street, Waltham, MA, United States, 02451
Analytics
WallStreet Target Price
16.1 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures COGT
Dividend Analytics COGT
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History COGT
Stock Valuation COGT
Financials COGT
Results | 2019 | Dynamics |